Skip to content
Veracyte® Press Releases

Veracyte® Press Releases

Date Title and Summary Additional Formats
Toggle Summary New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 22, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced that data published today in the Journal of the National Cancer Institute demonstrate that the company’s Decipher Prostate Genomic Classifier may help identify African American men with early,
View HTML
Toggle Summary Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 13, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that John Leite , Ph.D., has joined the company as senior vice president and general manager of Pulmonology & Market Access. Dr. Leite’s responsibilities will include leading commercial
View HTML
Toggle Summary New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer Data support Veracyte’s plan to expand test availability in the U.S.
View HTML
Toggle Summary New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
Findings presented at the European Respiratory Society International Congress 2022 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 7, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with
View HTML
Toggle Summary Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 1, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a fireside chat at the Morgan Stanley 20 th Annual Global Healthcare
View HTML
Toggle Summary Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
New data support continued expansion of the company’s tests, including determining treatment prognosis in men with advanced prostate cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 31, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company’s
View HTML
Toggle Summary New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
Findings suggest Veracyte’s immuno-oncology biomarkers could help predict response to therapy, improve patient outcomes and guide immunotherapy clinical trials SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 29, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced that new data published today in
View HTML
Toggle Summary Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 11, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced the appointment of Eliav Barr , M.D., to its board of directors, effective immediately. “We are thrilled to welcome Eliav Barr to our board,” said Marc Stapley , Veracyte’s chief executive
View HTML
Toggle Summary Veracyte Announces Second Quarter 2022 Financial Results
Grew Total Revenue to $72.9 million , an Increase of 32% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 2, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2022 .
View HTML
Toggle Summary Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
The Genomic Test Demonstrated 100 Percent Sensitivity and 100 Percent Specificity for MTC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 20, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in Thyroid show that the company’s RNA
View HTML